February 25, 2025. ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA PME), a member of the Eurobiomed ecosystem, has just secured 8.7 million euros as part of the i-Démo Call for Proposals under the France 2030 plan, operated by Bpifrance. This significant funding will support the clinical validation of an innovative biotherapy against generalized infection (sepsis), which affects over 49 million people and causes nearly 11 million deaths worldwide each year.
Endorsed by Eurobiomed's Strategic Projects Council in May 2024, this project fully aligns with the competitiveness cluster's roadmap, which notably aims to contribute to the market launch of 5 biopharmaceuticals. Eurobiomed's expertise, in close collaboration with the teams from Bpifrance and the Health Innovation Agency, was instrumental in assembling this strategic and complex project file, covering both scientific and medical aspects as well as bioproduction, thereby demonstrating its capacity to support the most ambitious projects in its region.
In 2024, Eurobiomed, a member of the French health cluster alliance Enosis Santé, secured 71.7 million euros in i-Démo public funding for its members, thus confirming the region's innovation dynamic. Production will be partly carried out by GTP Bioways, a major player in bioproduction and within the Eurobiomed community, illustrating the strength of the network and the synergies created within the ecosystem among these flagships of the Biotherapy Innovation Occitanie sector.
« This success once again demonstrates the relevance of our support, particularly in establishing robust funding strategies », emphasizes Emilie Royère, CEO of Eurobiomed. « The support provided to ABIONYX Pharma's dedicated team aligns perfectly with our mission to foster the emergence of tomorrow's European champions and confirms our region's position at the forefront of health innovation. »
« Eurobiomed's support was decisive in securing this funding », states Cyrille Tupin, CEO of ABIONYX Pharma. « This exemplary collaboration will accelerate the development of the first specific and targeted solution against sepsis, the third leading cause of mortality worldwide. »
